Histamine and its Effects Mediated via H3 Receptor – Potential Clinical Applications of H3 Antagonists

Open access

Abstract

Histamine is one of the most important biogenic amines and it mediates numbers of physiological processes. It is also involved in majority of inflammatory diseases via its receptors H1, H2, H3 and H4. The role of histamine had been recognized as substantial in many allergic diseases including bronchial asthma, thus the histamine receptor antagonists (H1) are frequently used in the clinical practice as potent anti-allergic and anti-inflammatory drugs. However, first generation of antihistamines have also adverse effects, predominantly sedation, changes in appetite and many more, and they are still not fully effective in all patients. Attention is now focused mainly on H3 and H4 receptor antagonists and their potential clinical applications. This review focuses basically on the H3 receptor, its expression pattern and some effects which are mediated by H3, discussing its clinical relevance

References
  • 1. White MV. The role of histamine in allergic diseases. J allergy Clin Immunol 1990; 57: 599-605.

  • 2. Greaves MW, Sabroe RU. Allergy and the skin. I - Urticaria Br Med J 1998;57:1147-1150.

  • 3. Friedmann PS. Assessment of urticaria and angio-oedema. Clin Exp Allergy 1999; 57: 109-112.

  • 4. Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009; 39: 1786-1800.

  • 5. Dale HH, Laidlaw PP. The physiological action of beta-imidazolylethylamine. J Physiol 1910; 41: 318-344.

  • 6. Dale HH, Laidlaw PP. Histamine shock. J Physiol. 1919; 52: 355-390.

  • 7. Popielski L. -Imidazolylathylamin und die Organextrakte Erster Teil: -Imidazolylathylamin als mechtiger Errezer der Magendrucken. Pfluegers Arch 1920; 178: 214-236.

  • 8. Lewis T., Grant T. Vascular reactions of the skin to injury. Part 11. The liberation of histamine - like substance in the injured skin, the underlying cause of factitious urticaria and of wheals produced by burning: and observations upon the nervous control of certain skin reactions. Heart 1924; 11: 209-265.

  • 9. Steinhoff M, Griffiths C, Church M, Lugar TA. Histamine. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s textbook of dermatology. Oxford, United Kingdom: Blackwell Science, 2004: 9. p. 50-52.

  • 10. Best CH., Dale HH., Dudey HW, Thorpe WV. The nature of the vasodilator constituents of certain tissues. J Physiol 1927; 62: 397.

  • 11. Endo Y. Simultaneous induction of histidine and ornithinedecarboxylases and changes in their product amines following the injection of Escherichia coli lipopolysaccharide intomice. Biochem Pharmacol 1982; 31:1643-1647.

  • 12. Szeberényi JB, Pállinger E, Zsinkó M, Pós Z, Rothe G, Orsó E, Szeberényi S, Schmitz G, Falus A, László V. Inhibition of effects of endogenously synthesized histamine disturbs in vitro human dendritic cell differentiation. Immunol Lett 2001; 76: 175-182.

  • 13. Radvány Z, Darvas Z, Kerekes K, Prechl J, Szalai C, Pállinger E, Valéria L, Varga VL, Sandor M, Erdei A, Falus A. H1 histamine receptor antagonist inhibits constitutive growth of Jurkat T cells and antigen-specific proliferation of ovalbumin-specific murineTcells. SeminCancer Biol 2000; 10: 41-45.

  • 14. Shiraishi M, Hirasawa N, Oikawa S, Kobayashi Y, Ohuchi K. Analysis of histamine-producing cells at the late phase of allergic inflammation in rats. Immunology 2000; 99:600-606.

  • 15. Maslinski C, Fogel WA. Catabolism of Histamine. In: Uvnäs B, editor. Handbook of experimental pharmacology. Histamine and histamine antagonists. Berlin-Heidelberg: Springer; 1991. P. 165-189.

  • 16. Schwelberger HG, Hittmair A, Kohlwein SD. Analysis of tissue and subcellular localization of mammalian diamine oxidase by confocal laser scanning fluorescence microscopy. Inflamm Res 1998; 47 Suppl 1: S60-1.

  • 17. Schwelberger HG, Bodner E. Purification and characterization of diamineoxidase from porcine kidney and intestine. Biochim Biophys Acta 1997; 1340: 152-164.

  • 18. Bieganski T, Kusche J, Lorenz W, Hesterberg R, Stahlknecht CD, Feussner KD. Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism. Biochim Biophys Acta 1983; 756: 196-203.

  • 19. Raithel M, Kufner M, Ulrich P, Hahn EG. The involvement of the histamine degradation pathway by diamineoxidase in manifest gastrointestinal allergies. Inflamm Res 1999; 48 Suppl 1: S75-76.

  • 20. Klocker J, Matzler SA, Huetz GN, Drasche A, Kolbitsch C, Schwelberger HG. Expression of histamine degrading enzymes in porcine tissues. Inflamm Res 2005; 54(suppl): S54-57.

  • 21. Brown DD, Tomchick R, Axelrod J. The distribution and properties of a histamine-methylating enzyme. J Biol Chem 1959; 234: 2948-2950.

  • 22. Kufner MA, Ulrich P, Raithel M, Schwelberger HG. Determination of histamine degradation capacity in extremely small human colon samples. Inflamm Res 2001; 50(suppl): S96-97.

  • 23. Schwelberger HG. Histamine N-methyltransferase (HNMT) enzyme and gene. In: Falus A, editor. Histamine: biology and medical aspects. Budapest, Hungary: Spring Med Publishing; 2004. p. 53-59. 24 Yamauchi K, Sekizawa K, Suzuki H, Nakazawa H, Ohkawara Y, Katayose D, Ohtsu H, Tamura G, Shibahara S, Takemura M, et al. Structure and function of human histamine N-methyltransferase: critical enzyme in histamine metabolism in airway. Am J Physiol 1994; 267(3 Pt 1): L342-349.

  • 25. Vlieg-BoerstraBJ, van der HeideS, Oude Elberink JN, Kluin-Nelemans JC, Dubois AE. Mastocytosis and adverse reactions to biogenic amines and histamine-releasing foods: what is the evidence? Neth J Med 2005; 63: 244-249.

  • 26. Ring J. Angewandte Allergologie. (Implemented allergology.) Munich, Germany: Urban & Vogel; 2004.

  • 27. White MV, Slater J, Kaliner M. Histamine and asthma. Am Rev Respir Dis 1987; 57: 1165-1176.

  • 28. Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr 2007; 85: 1185-1196.

  • 29. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem. 2000; 275:36781-3676.

  • 30. Nakamura T, Itadani H, Hidaka Y, Ohta M, Tanaka K. Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 2000; 279: 615-620.

  • 31. Milligan G, Bond RA, Lee M.Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 1995; 16:10-13.

  • 32. Ash AS, Schild HO. Receptors mediating some actions of histamine. 1966. Br J Pharmacol. 1997;120(4 Suppl): 302-314, discussion 300-301.

  • 33. Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, Nguyen S, Riley JP, Sun S, Williams KN, Edwards JP, Karlsson L. A potent and selective histamine H4 receptor antagonist with antiinflammatory properties. J Pharmacol Exp Ther 2004; 309: 404-413.

  • 34. LaBella FS, Queen GM, Brandes LJ. Interactive binding at cytochrome P-450 of cell growth regulatory bioamines, steroid hormones, antihormones, and drugs. J Cell Biochem 2000; 76: 686-694.

  • 35. Brandes LJ, Queen GM, LaBella FS. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isoenzymes that metabolize antineoplastic drugs. Cancer ChemotherPharmacol.2000; 45: 298-304.

  • 36. Paesen GC, Adams PL, Harlos K, Nuttall PA, Stuart DI. Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. Mol Cell 1999; 3: 661-671.

  • 37. Lieberman P. The basics of histamine biology. Ann Allergy Asthma Immunol 2011; 106 (2 Suppl): 2-5.

  • 38. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832-837.

  • 39. Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, Jackson MR, Erlander MG. Cloning and Functional Expression of the Human Histamine H3 Receptor Mol Pharmacol 1999; 55: 1101-1107.

  • 40. Bongers G, Bakker RA, Leurs R. Molecular aspects of the histamine H3 receptor. Biochem Pharmacol 2007; 73: 1195-1204.

  • 41. Drutel G, Peitsaro N, Karlstedt K, Wieland K, Smit MJ, Timmerman H, Panula P, Leurs R. Identification of rat H3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 2001; 59: 1-8.

  • 42. Tardivel-Lacombe J, Rouleau A, Héron A, Morisset S, Pillot C, Cochois V, Schwartz JC, Arrang JM. Cloning and cerebral expression of the guinea pig histamine H3 receptor: evidence for two isoforms.Neuroreport.2000;11:755-759

  • 43. Bonaventure P, Letavic M, Dugovic C, Wilson S, Aluisio L, Pudiak C, Lord B, Mazur C, Kamme F, Nishino S, Carruthers N, Lovenberg T. Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 2007; 73: 1084-1096.

  • 44. Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 2008; 31: 2163-2181.

  • 45. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001; 63: 637-672.

  • 46. Zhang M, Venable JD, Thurmond RL. The histamine H4 receptor in autoimmune disease. Expert Opin Investig Drugs 2006; 15: 1443-1452.

  • 47. Yu F, Bonaventure P, Thurmond RL. The Future Antihistamines: Histamine H(3) and H(4) Receptor Ligands. Adv Exp Med Biol 2010; 709: 125-140.

  • 48. Tiligada E, Zampeli E, Sander K, Stark H. Histamine H3 and H4 receptors as novel drug targets. Expert Opin Investig Drugs 2009; 18: 1519-1531.

  • 49. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000; 20: 131-147.

  • 50. Hough LB, Rice FL, H3 receptors and painmodulation: peripheral, spinal, and brain interactions. J Pharmacol Exp Ther 2011; 336: 30-37.

  • 51. Coruzzi G, Poli E, Morini G, Bertaccini G. The Histamine H3 Receptor. In Molecular Targets for Drug Development: GI Diseases. TS Gaginella, A Guglietta, editors. Totowa, NJ: Humana Press; 2000. p. 239-267.

  • 52. Coruzzi G, Morini G, Adami M, Grandi D. Role of histamine H3 receptors in the regulation of gastric functions. J Physiol Pharmacol 2001; 52(4 Pt 1): 539-553.

  • 53. Imamura M, Seyedi N, Lander HM, Levi R. Functional identification of histamine H3-receptors in the human heart. Circ Res 1995; 77: 206-210.

  • 54. Hashikawa-Hobara N, Chan NY, Levi R. Histamine 3 receptor activation reduces the expression of neuronal angiotensin II type 1 receptors in the heart. J Pharmacol Exp Ther 2012; 340:185-191.

  • 55. Gruber BL. Mastcells and basophils. In: Sigal LH, Ron Y, editors. Immunology and inflammation: basic mechanisms and clinical consequences New York: McGraw-Hill; 1994. p. 337-351.

  • 56. Suzuki S, Takeuchi K, Majima Y. Localization and function of histamine H3 receptor in the nasal mucosa. Clin Exp Allergy 2008; 38: 1476-1482.

  • 57. Nakaya M, Takeuchi N, Kondo K. Immunohistochemical localization of histamine receptor subtypes in human inferior turbinates. Ann Otol Rhinol Laryngol. 2004; 113: 552-557.

  • 58. Varty LM, Gustafsoo E, Laverty M, Hey JA. Activation of histamine H3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction. Eur J Pharmacol 2004; 484: 83-89.

  • 59. Ichinose M, Barnes PJ. Inhibitory histamine H3-receptors on cholinergic nerves in humana airways. Eur J Pharmaco1 1989; 163: 383-386.

  • 60. Ichinose M, Stretton C D, SchwaftzJ C, Barnes PJ. Histamine H3-receptors inhibit cholinergic neurotransmission in guinea-pig airways. Br J Pharmacol 1989; 97: 13-15

  • 61. Dimitriadou V, Rouleau A, Dam Trung Tuong M, Newlands GJ, Miller HR, Luffau G, Schwartz JC, Garbarg M. Functional relationship between mast cells and C-sensitive nerve fibres evidenced by histamine H3-receptor modulation in rat lung and spleen. Clin Sci (Lond) 1994; 87: 151-163

Acta Medica Martiniana

The Journal of Comenius University in Bratislava

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 15 15 15
PDF Downloads 3 3 3